血清クレアチニン2mg/dl以上の腎機能障害を有する多発性骨髄腫に対するボルテゾミブ・デキサメサゾン療法の意義

抄録

Here, we retrospectively assessed the reversibility of renal impairment and anti-myeloma effect of bortezomib and dexamethasone (BD therapy) for Japanese patients with multiple myeloma showing a serum creatinine level above 2 mg/dl. Improvement of renal impairment was observed in 6 of 7 patients following a median of 2.4 cycles of BD therapy. Three of 7 patients achieved more than partial response by BD therapy. The present study demonstrated that BD therapy was highly effective for the treatment of Japanese myeloma patients with renal impairment.